You are here:

Home
NICE Guidance
Conditions and diseases
Musculoskeletal conditions
Arthritis

Golimumab for the treatment of psoriatic arthritis

Technology appraisal guidance
Reference number: TA220
Published: 27 April 2011

Guidance
Tools and resources
Information for the public
Evidence
History

Psoriatic arthritis - golimumab: consultee and commentator comments on the ACD

Psoriatic arthritis - golimumab: Merck Sharp & Dohme (formerly Schering-Plough)
Psoriatic arthritis - golimumab: Psoriasis and Psoriatic Arthritis Alliance
Psoriatic arthritis - golimumab: Psoriasis Association
Psoriatic arthritis - golimumab: British Association of Dermatologists (endorsed by Royal College of Physicians)
Psoriatic arthritis - golimumab: British Health Professionals in Rheumatology
Psoriatic arthritis - golimumab: British Society for Rheumatology (endorsed by Royal College of Physicians)
Psoriatic arthritis - golimumab: Royal College of Nursing
Psoriatic arthritis - golimumab: Royal College of Pathologists
Psoriatic arthritis - golimumab: Abbott

This page was last updated: 11 March 2011